Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A systematic review and metanalysis of diagnostic yield of BAL for detection of SARS-CoV-2

Sumita Agrawal, MD, MRCP, DM\textsuperscript{a}, Akhil Dhanesh Goel, MD\textsuperscript{b}, Nitesh Gupta, MD, DM\textsuperscript{c,*}, Hari Kishan Gonuguntla, MD, DM\textsuperscript{d}, Henri Colt, MD, FAWM, FCCP\textsuperscript{e}

\textsuperscript{a} Consultant, Medipulse Hospital, Pulmonary Medicine and Critical Care Jodhpur, Jodhpur, Rajasthan, India
\textsuperscript{b} Associate Professor, Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India
\textsuperscript{c} Assistant Professor and Nodal Officer COVID19 Outbreak, Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, Address: Room no 638, 6th floor Super Speciality Block, New Delhi 110029, India
\textsuperscript{d} Consultant, Interventional Pulmonologist, Yashoda Hospital, Secunderabad, Hyderabad, 500003, India
\textsuperscript{e} Emeritus Professor, University of California, Irvine; Pulmonary and Critical Care Medicine, USA

\textbf{Article History:}
Received 4 August 2021
Revised 24 November 2021
Accepted 30 November 2021
Available online 13 December 2021

\textbf{ARTICLE INFO}

\textbf{Keywords:}
Bronchoalveolar Lavage
COVID-19
SARS-CoV-2
diagnostic testing [Supplementary Concept]

\textbf{ABSTRACT}

\textbf{Background:} The gold standard for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is microbiological confirmation by reverse transcriptase-polymerase chain reaction (RT-PCR)\textsuperscript{1} most commonly done using oropharyngeal (OP) and nasopharyngeal swabs (NP). But in suspected cases, where these samples are false-negative, bronchoalveolar lavage (BAL) may prove diagnostic.

\textbf{Objectives:} Hence, the diagnostic yield of BAL for detection of SARS-CoV-2 in cases of non-diagnostic upper respiratory tract samples is reviewed.

\textbf{Methods:} Databases such as MEDLINE, Scopus, and Google Scholar were searched using a systematic search strategy. The current study has been in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and has been registered with the International Prospective Registry of Systematic Reviews (CRD42020224088).

\textbf{Results:} 911 records were identified at initial database extraction, of which 317 duplicates were removed and, 596 records were screened for inclusion eligibility. We included total 19 studies in the systematic review, and 17 were included in metanalysis. The pooled estimate of SARS-CoV-2 positivity in BAL was 11\% (95\%CI: 0.01–0.24). A sensitivity analysis also showed that the results appear to be robust and minimal risk of bias amongst the studies.

\textbf{Conclusion:} The current study demonstrates that BAL can be used to diagnose additional cases primary disease and superadded infections in patients with severe COVID-19 lower respiratory tract infection.

© 2021 Elsevier Inc. All rights reserved.

\textbf{Introduction}

Microbiological confirmation by reverse transcriptase-polymerase chain reaction (RT-PCR) is considered the gold standard for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\textsuperscript{2} Oropharyngeal (OP) and nasopharyngeal swabs (NP) were most frequently used samples. While OP and NP swabs are the least invasive method of obtaining samples in patients with a contagious respiratory disease, false-negative results may result from sampling error or low amounts of virus in the collected sample (due to early or late sampling or patient having mild disease\textsuperscript{3}).

Studies have been done to evaluate the role of Bronchoalveolar lavage (BAL) in cases where NP and or OP swabs were non-diagnostic.

In Italy, Turriziani et al. described 15\% (n = 55) positivity in 367 BAL specimens to detect SARS-CoV-2 virus.\textsuperscript{4} In the United States, Chang et al. described 206 BAL specimens, reporting a positivity rate of zero percent.\textsuperscript{5} Yet, studies from China have shown BAL positivity between 93 and 100\%.\textsuperscript{6,7} Given the variability of these results, we conducted a systematic review and meta-analysis to assess the diagnostic yield of BAL for detection of SARS-CoV-2 in cases of non-diagnostic upper respiratory tract samples.

\textbf{Methods}

\textbf{Search strategy}

Databases such as MEDLINE, Scopus, and Google Scholar were searched using a systematic search strategy [Box1]. The search period included was from inception to 1st September 2021. Also, the
reference lists of selected articles were manually screened for potential articles eligible for inclusion. There were no restrictions regarding date or language in our search strategy. A re-run of the search strategy was done prior to the final analysis.

**Eligibility criteria**

Case-series and hospital-based cross-sectional studies describing patients with known COVID-19 (diagnosed by RTPCR positive on nasopharyngeal specimens) or suspected COVID-19 disease (high-risk of COVID-19 based on physician assessment of exposure history, symptoms and/or radiological features) and undergoing BAL for any indication were eligible for inclusion in this study.

**Data extraction**

Two reviewers independently screened records for potential inclusion. Disagreements were resolved after discussion with a third reviewer. Rayyan software was used for cataloguing and screening studies. Two independent reviewers used data extraction using a standardised format for the following variables: author name, place, study settings, patient demographic characteristics, clinical descriptions, and outcomes in terms of SARS-CoV-2 positivity. Disagreements in data extraction were resolved by discussion with a third reviewer. In case of missing or incomplete data, the authors were contacted for further details. Data extraction was done using a standard format in Microsoft Excel software (Table 1).

**Risk of bias**

Two independent reviewers critically appraised the selected cross-sectional studies for risk of bias using the Appraisal tool for Cross-Sectional Studies (AXIS) tool which evaluates various aspects of methodological quality using a 20 item questionnaire. The appraisal was qualitative and colour coded as green (no risk of bias), yellow (unclear risk of bias) or, red (high risk of bias).

The current study has been in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and has been registered with the International Prospective Registry of Systematic Reviews (CRD42020224088).

**Statistical analysis**

A random effects model was used to pool the percentage of BAL specimens that were positive for SARS-CoV-2. Study heterogeneity was estimated using the I-squared statistic. Study effects and publication bias were explored using Doi plot and Luis Furuya-Kanamori (LFK) index. Sensitivity analysis was done to assess the robustness of the pooled estimate. MetaXL software was used for the statistical analysis. A p value of less than 0.05 was considered significant. Studies with samples size less than 10 were excluded, and total 17 studies were included in final meta-analysis.
| No. | Study/place | Study Settings | Intervention | Outcome | BAL morphological findings | Other Microorganisms in BAL | Clinical Outcomes | Time |
|-----|-------------|----------------|--------------|---------|----------------------------|-----------------------------|---------------------|------|
| 2   | Yang Y[16]/China | Single centre study | n=410; median age: 47.5 (2-86) M: 47.1%; 120 (29.3%); NA | BAL (n = 66) | NA | NA | NA | NA |
|     | Patrucco F[17]/Italy | Multicentre, retrospective | n=131; median age: 64.65 (53.71−73.98) M: 71%; NA | BAL (n = 131) | 1. BAL positive 43/131 (32.8%) 2. virus other than SARS-CoV-2 in COVID 19 patients: 7%, Bacteria: 23%, Fungi: 7% | Virus (non-SARS-CoV-2) = 46 (35.11); Bacteria = 30 (22.90); Fungi = 19 (14.50) | At least 1 pathogen* = 46 (35.11) | NA |
|     | Abid MB[18]/USA | Single centre, retrospective | N=1516; (FOB=53) Ages: 76, 78, 77 All males; All had underlying malignancy | BAL=3 | BAL positive = 3 | NA | NA | NA |
|     | Mondoni M[19]/Italy | Multicentre, retrospective | N=109 (FOB=109) mean±SD age 60.0 ± 13.6 years M: 71% | BAL=78 | Bronchoscopy positive = 43/78 (55.1%) BAL positive = 35/61 (57.4%) Bronchial washing positive = 8/17 (47.1%) Fungal infections: 4 | Lower respiratory tract confection (n = 4) | NA | March 1, and April 15, 2020 |
|     | Geri P[20]/Italy | Single centre, retrospective | N=79 Mean age 65 ± 17 years M: 75% | BAL=79 | BAL positive = 2/79 | NA | NA | 14 March 2020 and 4 May 2020 |
| 7   | Vannucci J[21]/Italy | Single centre, retrospective study | N=81 Mean age: 68.3 ± 16.2 M: 62%; NA | BAL=81 | BAL positive = 3/81 (3.7%) Associated infections: 0 | Haemophilus para-influenzae 4 (4.9) Staphylococcus aureus 3 (3.7) Pseudomonas aeruginosa 3 (3.7) Klebsiella pneumoniae 2 (2.5) Enterobacter aerogenes 1 (1.2) Enterococcus faecium 1 (1.2) Streptococcus pneumoniae 1 (1.2) Haemophilus influenzae 1 (1.2) | NA | NA | (continued on next page)
| S. No | Study/place | Study Settings | Patient number; Age; Males; Comorbidities | Intervention | Outcome | BAL morphological findings | Other Organisms in BAL | Clinical Outcomes | Time |
|-------|-------------|----------------|-------------------------------------------|-------------|---------|---------------------------|----------------------|-----------------|-------|
| 8     | Ora J9, Italy | Single Centre | N = 28; mean ± SD: age 65 ± 16; M: 57%; NA | BAL = 28 | BAL positive = 0 | NA | NA | NA | March 13th and April 30th, 2020, |
|       | Ramos KJ, 26 USA | Single centre | N = 16; mean age ± SD: 59 ± 14; M: 50%; NA | BAL = 16 | BAL positive = 3/16 (19%) | NA | NA | NA | March 26 - April 17, 2020 |
| 10    | Wang W, China | Multicenter | N = 205; FOB = 28; Mean age: 44 years, range: 5-67 years; M: 68% | BAL = 15 | Brush Biopsy = 13 | NA | NA | NA | January 1 through February 17, 2020 |
| 11    | Liu R, China | Single centre, retrospective study | N = 4880; FOB = 5; Median Age was 50 years (IQR=27); M: 66.13%; NA | BAL = 5 | BAL positive = 5/5 (100%) | NA | NA | NA | January 22 to February 14, 2020 |
| 12    | Turriani O, Italy | Single Centre | N = 6565; FOB = 367; median age was 57, IQR: 41–73 | BAL = 367 | BAL positive = 55/367 (15%) | NA | NA | NA | 6 March through 4 May 2020 |
| 13    | Chang J, USA | Single centre | N = 177; (FOB=206); Mean age ± SD: 59.0 ± 14.5; M: 54%; Lung Transplant 66 (37.3%); COPD/Asthma 36 (20.3%); Interstitial Lung Disease 32 (18.1%) | BAL = 206 | BAL positive = 0 | NA | NA | NA | April 13, 2020, and July 10, 2020 |
| 14    | Challener D, USA | Single Centre | N = 34; NA; M: 53%; NA | BAL = 34 | BAL positive = 0 | NA | Fungal n = 5; Viral n = 4; Bacterial n = 7; Mycobacteria n = 2 | NA | February 6, 2020 and February 20, 2020 |
| 15    |             |                |                                           |             |         |                             |                      |                 |       |
| S. No | Study/place          | Study Settings | Patient number; Age; Males; Comorbidities | Intervention | Outcome | BAL morphological findings | Other Microorganisms in BAL | Clinical Outcomes | Time                        |
|-------|----------------------|----------------|-------------------------------------------|--------------|---------|----------------------------|----------------------------|-----------------|---------------------------|
| 16    | Barberi et al., Italy| Single centre, retrospective study | N = 198  Median Age: 70 years, IQR: 58–78 M = 54%; NA | Total BAL=198 BAL in NP negative=198 | BAL positive:32 (16%) | NA | NA | NA | March 1, 2020 until April 30, 2020 |
| 17    | Clercq et al., Belgium | Single centre, retrospective study | N = 405  Mean age: 56.8 ± 13.3 years M:59.3%; Any concomitant disease 16 (80%) Hypertension 4 (20%) Malignancy 7 (35%) Chronic kidney disease 6 (30%) Chronic cardiac disease 6 (30%) Chronic pulmonary disease, not asthma 4 (20%) Asthma 4 (20%) | Total BAL=27 BAL in NP negative=27 | BAL positive = 7 | NA | H. influenzae =3  S. Pneumoniae = 1  M. Pneumoniae =1  E. coli. = 2 | NA | 19 March 2020 and 30 April 2020 |
| 18    | Mahmood et al., USA  | Multicentre, retrospective study | N = 53; Median Age: 62 years, IQR: 46–69 M = 67.9%; Diabetes 17 (32.1) Congestive heart failure 9 (17.1) Coronary Artery Disease 13 (24.5) Hypertension 14 (26.4) Cirrhosis 4 (7.5) Chronic kidney disease 12 (22.6) Thrombocytopenia 4 (7.5) Malignancy 8 (15.1) Lung Transplant 7 (13.2) Chronic obstructive lung disease 7 (13.2) | Total BAL=53 BAL in NP negative=53 | BAL positive = 1 | NA | NA | NA | 1 March 2020 and 31 July 2020 |
| S. No | Study/place | Study Settings | Patient number; Age; Males; Comorbidities | Intervention | Outcome | BAL morphological findings | Other Microorganisms in BAL | Clinical Outcomes | Time |
|-------|-------------|----------------|------------------------------------------|--------------|---------|---------------------------|-----------------------------|------------------|------|
| 1 | Oberg et al., USA | Multicentre, prospective study | N = 189; Average Age: 60.8 years, M = 58%; Comorbid conditions: Hypertension 46 (24.3%), Diabetes mellitus II 33 (17.5%), Malignancy, not lung 31 (16.4%) | Total BAL=189 BAL in NP negative=189 | BAL positive = 0 | NA | NA | NA | March 15, 2020, and November 9, 2020, |

FOB - Fibreoptic Bronchoscopy; BAL - Bronchoalveolar Lavage; SARS-CoV-2 - Severe Acute Respiratory Syndrome Coronavirus 2; M - Male; IQR- Inter Quartile Range; NA - Not Available.
Results

911 records were identified at initial database extraction, of which nineteen articles were included in our systematic review after which two articles where BAL was done in only ten or less patients were excluded. In total, 17 articles were therefore included in the final meta-analysis (Fig. 1).

The pooled estimate of SARS-CoV-2 positivity in BAL was 11% (95%CI: 0.01–0.24) (Fig. 2). The robustness of this estimate was indicated by minor asymmetry in the Doi plot (Fig. 3). There was high heterogeneity in the estimate of the pooled proportion ($I^2 = 96\%$). Further investigation using sensitivity analysis found that the exclusion of none of the studies significantly affected the pooled estimate (Fig. 4). Also, there appeared to be minimal risk of bias amongst the

![PRISMA flow diagram depicting the flow of information through different phases of systematic review.](image-url)
studies, particularly regarding the description of non-responders and few regarding sample size justification (Fig. 5).

**Discussion**

This meta-analysis attempts to assess the outcomes of BAL in detecting SARS-CoV-2 in patients with negative NP and or OP swabs by RT-PCR. We included a total of 19 studies in the systematic review, and 17 were included in the metaanalysis. There was minimal risk of bias amongst the studies. A sensitivity analysis also showed that the results appear to be robust and not dependent on any individual study results.

BAL is an excellent method for the microbiological diagnosis of lung infections, especially in immunocompromised patients. Studies have shown the detection rate of various microorganisms in BAL fluid to range between 50 and 73%. The microbiologic and molecular diagnostic testing of BAL samples widely available for etiology (bacterial, viral and, fungal) of pneumonia. Notably, diffuse alveolar hemorrhage (DAH), foamy alveolar macrophages and, a gamut of BAL cellular findings (eosinophilic, lymphocytic, or neutrophilic predominance) may be diagnostic or relatively so for pulmonary infections. BAL diagnostic utility is reportedly 34–59%; etiologies include undiagnosed causes of acute hypoxic respiratory failure, ventilator-associated pneumonia, and secondary infections. The latter is vital in terms of restricting superfluous antibiotic usage. The drawback of BAL is the lack of ability to differentiate between colonizers and active infection by the recovered pathogenic microorganisms in the absence of clinical disease.
We have tried to analyze BAL’s role in diagnosing SARS CoV-2 infection when nasopharyngeal swabs are negative. The basis for the hypothesis that the virus may be detected in such cases is that the angiotensin-converting enzyme 2 (ACE2) binding affinity of the S protein is an important determinant of SARS-CoV-2 infectivity and disease severity. Studies have shown the predominance of these receptors in the lower respiratory tract and SARS CoV-2 having higher receptor tropism in the lower respiratory tract. Although studies have a wide range of positivity, a pooled estimate of 11% suggests that BAL may be used to confirm SARS CoV-2 infection where nasopharyngeal specimens are negative, and there is high clinical or radiological suspicion.

There are multiple studies of BAL performed in COVID-19 patients for microbiological sampling. The BAL specimen served two purposes: for patients with negative nasopharyngeal swabs for SARS-CoV-2, it provided an additional source for microbiological confirmation and diagnosing superadded infections. Studies also showed a predominance of neutrophils in these patients, which may be due to superadded bacterial or viral infections or simply a supplementary finding in severe COVID-19 acute respiratory distress syndrome (ARDS) patients. Gelarden et al. compared the results of BAL cytopathology with clinical outcomes. In this study, longer hospital stay (\( p < 0.05 \)) and longer requirement for mechanical ventilation (\( p < 0.05 \)) was associated with BAL lymphocytosis, and the median atypical (activated) lymphocyte count was associated with shorter hospital stay (\( p < 0.05 \), shorter time on mechanical ventilation (\( p < 0.05 \)) and improved survival. Dentone et al. compared the analysis of BAL cellularity with clinical outcomes in patients on invasive mechanical ventilation. The majority of cells in their BAL analysis were neutrophils (70%, IQR 37.5–90.5) and macrophages (27%, IQR 7–49), while a minority were lymphocytes, 1%, TCD3+92% (IQR 82–95). Their ICU mortality was 32.8%. The non-survivors were of the older age group (\( p = 0.033 \)), and their peripheral lymphocytes (\( p = 0.012 \)) were lower than the survivors. The multivariate analysis showed that the percentage of macrophages in the BAL also correlated with poor outcome (OR 1.336, CI95% 1.014–1.759, \( p = 0.039 \)).

Earlier in the pandemic, consensus statements suggested limiting bronchoscopy to urgent indications, and COVID-19 positivity was listed as a relative contraindication. Some guidelines suggested bronchoscopy could be performed in these patients with appropriate precautions. Studies also demonstrated that performing BAL had a significant role in decision-making, especially in severe ARDS patients. Yang et al. observed that the yield in severe cases was greater at 8–14 days and >15 days compared to mild cases. Also, severe cases were more commonly seen in higher age groups and male gender. A few studies assessed for superadded infections and found associated viral, fungal, and bacterial organisms.

Although specific CT scan of thorax features such as bilateral ground-glass opacities mixed with consolidation, mainly peripheral, suggestive of SARS CoV-2 infection, CT scan has low specificity (25%). Thus, microbiological confirmation may be necessary when an alternative diagnosis is suspected. Studies to correlate the CT scan features with BAL findings have shown that patients with SARS-CoV-2 infection had more CT alterations than the SARS-CoV-2-negative patients, suggesting CT scan may add substantial evidence in the diagnosis of this infection.

Risks to the patient of performing BAL are similar to that of flexible bronchoscopy, including hypoxemia, fever, bronchospasm, and...
more rarely, pneumothorax. In the setting of COVID-19, as for other infectious diseases, an additional risk is an infection of health care workers.34

One of the limitations of this review is the dynamicity of the current COVID-19 situation. The current evidence is still developing and is likely to demand revisions in the current estimates quickly. However, the prevalence estimates in the current study do provide an insight into the diagnostic utility of BAL in COVID-19.

**Conclusion**

The current study demonstrates that BAL can be used to diagnose additional cases of primary disease and superadded infections in patients with severe COVID-19 lower respiratory tract infection when NP and or OP swabs are negative for RT-PCR SARS-CoV-2. Further, well-designed prospective studies are needed to substantiate these findings and inform guidelines for BAL in COVID-19 and other respiratory infections.
References

1. World Health Organization; Geneva: 2020. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases. https://apps.who.intiris/bitstream/handle/10655/331501/WHO-COVID-2019-laboratory-2020-eng.pdf?sequence=1&isAllowed=y.

2. Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv. 2020. https://doi.org/10.1101/2020.02.11.20021493. [cited 2021 Jan 27].

3. Turrizziani O, Scandra I, Mazzutti L, Di Carlo D, Bitossi C, Calabretto M. SARS-CoV-2 diagnostics in the virology laboratory of a university hospital in Rome during the lockdown period. J Med Virol. 2021;93(2):886–891.

4. Chang J, Swenson KE, Sung A, Bedi H. Coronavirus disease 2019 test correlation between nasopharyngeal swab and BAL in asymptomatic patients. Chest. 2020;112. doi:10.1016/j.chest.2020.11.006.

5. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA Am Med Assoc. 2020;323(18):1843–1844.

6. Liu R, Han H, Liu F, Lv Z, Wu K, Liu Y. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Chin Clin Chems. 2020;505:172–175. Journal Infect Public Heal.

7. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535.

8. Barberi C, Castelnuovo E, et al. Bronchoalveolar lavage in suspected COVID-19 cases with a negative nasopharyngeal swab: a retrospective cross-sectional study in a high-impact northern Italy area. Intern Emerg Med. 2021;16(7):1857–1864. Available from: https://pubmed.ncbi.nlm.nih.gov/33770367/.

9. Kamran M, Matt A, et al. Low utilisation of bronchoscopy to assess COVID-19 respiratory infection: a multicenter experience. BMJ Open Respir Res. 2021;8(1):e000962. Available from: https://pubmed.ncbi.nlm.nih.gov/34301717/.

10. Catherine AC, Cuttica JM, Elizabeth SM, Christine A, Richard GW, Sean BS. Comparing nasopharyngeal and BAL SARS-CoV-2 assays in respiratory failure. Am J Respir Crit Care Med. 2021;203(1):2020–2022.

11. Jozefien DC, Thomas Lucien Aimé M, et al. Diagnosing COVID-19: towards a feasible COVID-19 rule-out protocol. BMJ Open Respir Res. 2021;8(1):e000962. Available from: https://pubmed.ncbi.nlm.nih.gov/33586631/.

12. Oberg CL, et al. Pre-procedural COVID-19 nasopharyngeal swab has good concordance with bronchoalveolar lavage in patients at low risk for viral infection. Respir. 2021;110(6):510–514. Available from: https://pubmed.ncbi.nlm.nih.gov/33784700/.

13. Baron A, Hachem M, Tran Van Nhieu J, Botterel F, Fourati S, Carteaux G. Bronchoalveolar lavage in COVID-19 patients with invasive mechanical ventilation for ARDS. Ann Am Thorac Soc. 2020;0. https://doi.org/10.1164/rccm.201202-0320ST.

14. Vannucci J, Ruberto F, Diso D, et al. Collaborators. Usefulness of bronchoalveolar lavage in COVID-19 patients with invasive mechanical ventilation for ARDS. Chest. 2020;158(3):1268–1275. https://doi.org/10.1016/j.chest.2019.09.039.

15. Hani MM, Shojaei S, Lamb CR, Ozt D, Maldonado F, Eapen E. The use of bronchoscopy during the coronavirus disease 2019 pandemic: chest/AABIP guideline and expert panel report. Chest. 2020;158(3):1268–1281. Sep 1.

16. Bilal Abid M, Chhabra S, Buchan B. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021;14(1):65–70.

17. Vannucci J, Roberto F, Diso D, et al. Collaborators. Usefulness of bronchoalveolar lavage in suspect COVID-19 repeatedly negative swab test and interstitial lung disease. J Clin Microbiol Infect. 2020;23:67–69.

18. Ora J, Pozzeddu E, Cavalli F, Giorgino FM, Girolami A, Chiocchi M. Does bronchoscopy help the diagnosis in COVID-19 infection? Eur Respir J. 2020;56(2):8–10. https://doi.org/10.1183/13993003.01619-2020.

19. Ramos RJ, Knapadak SG, Collins BF, Pottinger PS, Wall R, Mays JA. Detection of SARS-CoV-2 by bronchoscopy after negative nasopharyngeal testing: stay vigilant for COVID-19. Respir Med Case Rep. 2020;30:101120. https://doi.org/10.1016/j.rmcr.2020.101120.

20. Geri P, Salton F, Zucatosta I, Tamburrini M, Biolo M, Busca A. Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study. Eur Respir J. 2020;56(4):3–4. https://doi.org/10.1183/13993003.01733-2020.

21. Challener D, Shah A, Binnicker M, Badley A, O’Horo J. Retrospective SARS-CoV-2 real-time PCR testing of stored Bronchoalveolar lavage samples from February 2020. Mayo Clin Proc. 2020;95(9):1942–1945.

22. Kim SW, Rhe C, Kang HS, Lee HY, Kang JY, Kim SJ. Diagnostic value of bronchoscopy in patients with hematologic malignancy and pulmonary infiltrates. Ann Hematol. 2015;94(1):153–159. Available from: https://pubmed.ncbi.nlm.nih.gov/25602720/.

23. Bissinger AL, Eisele H, Hamprecht K, Schumacher U, Kandolf R, Loeffler J. Infectious pulmonary complications after stem cell transplantation or chemotherapy: diagnostic yield of bronchoalveolar lavage. Diagn Microb Infect Dis. 2005;52(4):275–280. [cited 2021 Jan 22] Available from: https://pubmed.ncbi.nlm.nih.gov/15936168/.

24. Hardak E, Avivi I, Berkun L, et al. Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. Infection. 2016;44(4):491–497. https://doi.org/10.1007/s10150-016-0873-3.

25. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–1014. https://doi.org/10.1164/rccm.201202-0210ST.

26. Crecco C, Farrioukh M, Prodanovic H, Azoulay E, Chenivesse C, Lorut C. Safety of performing fiberoptic bronchoscopy in critically ill hypoxemic patients with acute respiratory failure. Intensiv Care Med. 2013;39(1):45–52. [cited 2021 Feb 1] Available from: https://pubmed.ncbi.nlm.nih.gov/23070123/.

27. Salzer HFJ, Schaefer G, et al. Linical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jiroveci pneumonia. Respiration. 2018;96:56–65. S. Karger AG [cited 2021 Feb 1]. p. Available from: https://pubmed.ncbi.nlm.nih.gov/29635251/.

28. Oz M, Lorke DE. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomed Pharma- cother. 2021;136:111193. [cited 2021 Jan 20] Available from: http://www.ncbi.nlm.nih.gov/pubmed/33461019.

29. Ian G, et al. Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes. Hum Pathol. 2021;113:92–103. [cited 2021 Sep 14] Available from: https://pubmed.ncbi.nlm.nih.gov/33905777/.

30. Dentone C, Vena A, Locante M, Grillo F, Brunetti I, Barisone E. Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. BMC Infect Dis. 2021;21(1):4–21. [cited 2021 Sep 14] Available from: https://bmccinetdis.biomedcentral.com/articles/10.1186/s12879-021-00615-9.

31. Wahidi MM, Shojaei S, Lamb CR, Ozt D, Maldonado F, Eapen E. The use of bronchoscopy during the coronavirus disease 2019 pandemic: chest/AABIP guideline and expert panel report. Chest. 2020;158(3):1268–1281. Sep 1.